Phase 1a and Phase 2 Study for PK, PD, Safety and Preliminary Efficacy of ST-067


Study Number
1075721
Phase
I/II
Age Group
Adult
Purpose

This is a multicenter Phase 1a open-label, dose escalation study, and a Phase 2 study of ST-067. Phase 1a is a first-in-human (FIH) dose escalation study in patients aged 18 years or older diagnosed with solid tumors who have exhausted available standard. Phase 2 will enroll patients aged 18 years or older diagnosed with the following solid tumors: melanoma, renal cell carcinoma, triple negative breast cancer, non-small cell lung cancer, squamous cell carcinoma of the head and neck, and microsatellite instability-high tumors.

Full Title

A PHASE 1A OPEN-LABEL, DOSE-ESCALATION, AND A PHASE 2 STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF ST-067 ADMINISTERED SUBCUTANEOUSLY AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS

ClinicalTrials.Gov ID
NCT04787042

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.